tiprankstipranks
Qianhai Health Holdings Ltd. (HK:0911)
:0911
Hong Kong Market
Want to see HK:0911 full AI Analyst Report?

Qianhai Health Holdings Ltd. (0911) AI Stock Analysis

0 Followers

Top Page

HK:0911

Qianhai Health Holdings Ltd.

(0911)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 5.2)
Rating:73Outperform
Price Target:
HK$0.71
▲(155.00% Upside)
Action:Upgraded
Date:05/17/26
The score is driven primarily by improved financial performance (return to profitability, stronger operating/free cash flow, and very low leverage), supported by constructive technical trends with the stock trading above key moving averages. Valuation is relatively modest on P/E, though the lack of dividend yield data tempers that component.
Positive Factors
Conservative Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility, reducing refinancing and bankruptcy risk. This stability supports capital allocation for R&D, regulatory milestones or opportunistic M&A without pressuring cash flows, sustaining operations through industry cycles.
Negative Factors
Very Thin Profit Margins
Extremely low gross and net margins constrain the company's ability to convert revenue into meaningful returns. Such compressed margins leave little room to absorb cost inflation, pricing pressure or higher SG&A, limiting sustainable profitability and resilience to industry headwinds.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility, reducing refinancing and bankruptcy risk. This stability supports capital allocation for R&D, regulatory milestones or opportunistic M&A without pressuring cash flows, sustaining operations through industry cycles.
Read all positive factors

Qianhai Health Holdings Ltd. (0911) vs. iShares MSCI Hong Kong ETF (EWH)

Qianhai Health Holdings Ltd. Business Overview & Revenue Model

Company Description
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health...
How the Company Makes Money
null...

Qianhai Health Holdings Ltd. Financial Statement Overview

Summary
Financials show a meaningful turnaround: profitability returned in 2024–2025 and cash generation improved sharply in 2025, while leverage is extremely low. The main constraint is very thin profitability (low gross and net margins) and margin compression in 2025 versus 2024, suggesting the recovery is still fragile.
Income Statement
58
Neutral
Balance Sheet
84
Very Positive
Cash Flow
74
Positive
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue677.12M519.70M961.29M1.96B283.40M
Gross Profit22.26M29.67M-35.60M76.48M16.04M
EBITDA7.39M15.64M-50.23M-231.24M2.06M
Net Income5.94M1.31M-52.70M-233.70M-888.00K
Balance Sheet
Total Assets408.39M407.31M478.12M534.43M738.63M
Cash, Cash Equivalents and Short-Term Investments61.38M23.51M19.52M1.64M2.47M
Total Debt424.00K1.03M487.00K1.19M7.83M
Total Liabilities17.19M21.74M94.00M97.73M68.09M
Stockholders Equity391.20M385.57M384.11M436.70M670.53M
Cash Flow
Free Cash Flow38.78M4.19M857.00K-5.26M-44.19M
Operating Cash Flow38.80M4.20M857.00K-5.26M-44.18M
Investing Cash Flow-14.00K246.00K17.77M12.34M46.84M
Financing Cash Flow-648.00K-712.00K-743.00K-7.91M-16.56M

Qianhai Health Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.28
Price Trends
50DMA
0.70
Negative
100DMA
0.49
Positive
200DMA
0.39
Positive
Market Momentum
MACD
-0.03
Positive
RSI
48.77
Neutral
STOCH
56.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Positive. The current price of 0.28 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.70, and below the 200-day MA of 0.39, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 56.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0911.

Qianhai Health Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
HK$108.44M30.480.91%30.29%355.84%
69
Neutral
HK$1.98B6.8912.91%15.40%-0.47%-0.33%
54
Neutral
HK$185.60M-0.48-30.35%-11.89%-290.48%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
46
Neutral
HK$317.60M77.78-1.17%7.50%-8.30%-44.44%
45
Neutral
HK$157.81M-3.45-30.35%-12.03%6.24%
44
Neutral
HK$184.90M-2.61-11.18%-2.12%-13.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0911
Qianhai Health Holdings Ltd.
0.64
0.41
178.26%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.06
-0.02
-23.81%
HK:0455
Tianda Pharmaceuticals Ltd.
0.09
-0.05
-36.30%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.29
-0.02
-5.00%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.21
-41.00%
HK:2633
Jacobson Pharma Corporation Limited
1.04
-0.47
-31.13%

Qianhai Health Holdings Ltd. Corporate Events

Qianhai Health Wins Unanimous Shareholder Backing at AGM
Jun 17, 2026
Qianhai Health Holdings shareholders approved all resolutions at the annual general meeting held on 17 June 2026, with 100% of votes cast in favour of each item. The meeting endorsed the audited financial statements for the year ended 31 December ...
Qianhai Health Sets June 2026 AGM to Approve Results and Board Changes
May 12, 2026
Qianhai Health Holdings Limited has called its annual general meeting for 17 June 2026 in Hong Kong, where shareholders will review and approve the audited consolidated financial statements for the year ended 31 December 2025. The meeting will als...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 17, 2026